RecruitingPhase 1NCT06026410
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kura Oncology, Inc.
- Intervention
- Darlifarnib(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona, United States
- University of Southern California, Los Angeles, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- UCLA Department of Medicine, Los Angeles, California, United States
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- AdventHealth Celebration, Celebration, Florida, United States
- Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida, United States
- Florida Cancer Specialists, Sarasota, Florida, United States
- University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- OU Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Mirati Therapeutics Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06026410 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07185997Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsArriVent BioPharma, Inc.